A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02980315

Enrollment

Registered

2016-12-02

Start date

2016-11-30

Completion date

2017-12-31

Last updated

2016-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Neoplasms

Keywords

nasopharyngeal carcinoma, EBV related cancers

Brief summary

The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.

Detailed description

Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.

Interventions

OTHERCAR-T cells

the patients treat with CAR-T cells

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of nasopharyngeal carcinoma

Exclusion criteria

* •pregnant woman * severe autoimmune diseases * serious infection

Design outcomes

Primary

Measure	Time frame
all cause mortality	one year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026